Several other studies showed that CS1 is overexpressed on multiple myeloma (MM) and a humanized anti-CS1 mAb (Elotuzumab/Empliciti) was approved as a break through drug for treatment for MM patients[39,40]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.